Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.
$32.52-4.91%
报价 2026-11-06
市值
$993.5M
EV
$1.07B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -24.4%
$18.15$43.04
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | -0.77 → -0.93 | — |
| FY+32028-12 | 1.3x | -0.77 → -0.35 | — |
毛利率 77% · TTM 收入 $377M · 基数 EPS -0.77（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CSTLCastle Biosciences, Inc. | $993.5M | -4.9% | +11.2% | 77.1% | – | – | – | |
| CDNACareDx, Inc | $4.13B | +2.9% | +40.1% | 71.1% | 31.6x | 136.9x | 68.7x | 高增长 |
| VIRVir Biotechnology, Inc. | $2.07B | +10.8% | +678.4% | 97.2% | – | – | – | |
| PSNLPersonalis, Inc. | $1.71B | +1.5% | +19.4% | 21.2% | – | – | – | |
| AMNAMN Healthcare Services, Inc. | $1.4B | -23.7% | +24.0% | 30.6% | 17.4x | 6.4x | 4.1x | Cheap GARP |
| FLGTFulgent Genetics, Inc. | $653.2M | +27.2% | +8.5% | 33.8% | – | – | – | |
| GERNGeron Corporation | $635.9M | +4.2% | +25.5% | 66.7% | – | – | – | |
| MYGNMyriad Genetics, Inc. | $566.2M | -5.9% | +5.1% | 68.8% | – | – | – | |
| EVHEvolent Health, Inc. | $515.2M | +0.9% | +40.5% | 12.9% | – | – | 31.9x | |
| 同行中位数 | – | – | +24.7% | 50.3% | 24.5x | 71.7x | 31.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.5M | $83.7M | $87M | $83M | $86.2M | $88M | $86.3M | $85.8M |
| Gross Margin | 77.1% | 75.5% | 79% | 77.5% | 79.5% | 81.4% | 81.3% | 81.8% |
| Operating Margin | -3% | -22% | -4.4% | -8.2% | -4.9% | -31.7% | 4.7% | 5.9% |
| Net Income | $-2.1M | $-14.5M | $-2.3M | $-501,000 | $4.5M | $-25.8M | $9.6M | $2.3M |
| Diluted EPS | -0.07 | -0.49 | -0.08 | -0.02 | 0.15 | -0.9 | 0.32 | 0.08 |
| Operating Cash Flow | $15.2M | $-22.1M | $26.9M | $22.6M | $20.8M | $-6M | $24.4M | $23.3M |